# Multus Media Financial Model B2B supplier of animal-free cell culture growth media (serum substitutes) for the cultivated meat industry. - Canonical: https://finamodel.com/startups/multus-media - Excel download: https://finamodel.com/startup-models/multus-media.xlsx - Category: Biotech/Pharma - Model type: SaaS ARR / Valuation - Funding round: Seed - Funding: $21M - Founded: 2021 - Geography: UK (incorporated as MULTUS Biotechnology Limited); global customer ambition. - Customer: B2C ## About the company Multus Media supplies animal-free growth media for cultivated-meat producers. Its Proliferum M and other serum substitutes aim to replace fetal bovine serum, an ethically problematic and costly input not designed for food production, with scalable, economically viable alternatives. Revenue is a B2B reagent and ingredient model: products are sold directly to cultivated-meat companies and research labs during R&D, then to scale-up customers and eventually commercial producers. The deck describes no subscription element, pricing, volumes, contracts, or customer count, so qualification timing is central to the forecast. The company lists collaborations with Imperial College London, Innovate UK, IndieBio, the Royal Academy of Engineering, SYNBICITE, and EIT Climate-KIC. No financial metrics are disclosed. The model should build customer qualification, litres sold, price, manufacturing cost, R&D, capacity, working capital, and commercial adoption rather than software ARR. ## What's included - 5-year monthly revenue build with stage-appropriate growth assumptions - Full P&L, headcount plan, and operating-expense schedule - Cash-flow statement, runway, and burn-rate tracking - Valuation via exit multiple with a DCF cross-check - Returns analysis with MOIC and IRR - Unit economics including CAC, LTV, payback, and cohort retention ## Product & value proposition Three branded growth media products: - **Proliferum M™** - 10:1 solution, animal-free serum substitute, designed by MULTUS. - **Serum P™** - serum substitute (partial name redacted). - Product **"im A™"** - serum substitute (name partially redacted). Core value proposition: high performance, scalable/efficient, economically viable. Existing solutions use animal-derived fetal bovine serum (FBS), which is ethically problematic, costly, and not designed for food production. Multus replaces FBS with animal-free alternatives, addressing the >X% cost share that growth media represents in cultivated meat production (exact % redacted in deck). ## Market - Alternative/cultivated meat market: **$630bn** by 2040, representing **35% share** of the global meat industry. - Cultivated meat CAGR 2025–2040: redacted in deck. - Volume of growth media demanded in 2030: redacted in deck. - Demand trajectory: Three phases shown in area chart - (1) R&D / establishing production process, (2) Scale-up + high-end restaurants, (3) Commercialisation at large scale. Market set to "explode" in 20XX (year redacted); CAGR estimate redacted. - Consumer willingness to pay: 58% of 193 people surveyed (2019) would pay a **37% premium** for cultured meat vs. conventional meat. - Sustainability driver: 87% GHG reduction vs. conventional meat; 0 mg antibiotics. ## Revenue model - **B2B reagent/ingredient sales**: sell growth media products (Proliferum M™ and others) to cultivated meat companies for R&D and, eventually, scaled production. - Channels: direct to cultivated meat producers and academic/research labs (inferred from stage and product type). - Initial channel: R&D customers exist now; scale-up/high-end restaurant channel is near-term; large-scale commercialisation is long-term. - No subscription or SaaS element apparent; pure product/volume revenue model. ## Traction & metrics - No revenue figures disclosed. - No customer counts disclosed. - Collaborative partnerships listed: Imperial College London, UK Research and Innovation (Innovate UK), IndieBio, Royal Academy of Engineering, SYNBICITE, EIT Climate-KIC, C/M/S Law. - McKinsey & Co. Venture Academy consulting support. - Cost of cultivated meat production falling: timeline shown from 2013 (per burger), 2016 (per kg), 2019 (per gram) - specific dollar values redacted. - Industry investment to bring costs to commercial viability: bar chart of money raised ($mn) shows increasing trend through multiple years - all values redacted. ## Competition / moat - Existing solutions use animal-derived blood serum (FBS), which was "never designed for the food industry". - Moat framing: proprietary formulation (Proliferum M™ branded 10:1 concentrate format suggests cost/logistics advantage); animal-free, food-safe positioning differentiates from pharma-grade FBS. - No named competitors cited in deck. ## Team & funding ask / use of funds **Co-founders**: - Cai Linton - CEO - Kevin Pan - CTO - Reka Tron - COO **Advisory board**: slide present but content redacted. **Accelerators & grants**: IndieBio, Royal Academy of Engineering, EIT Climate-KIC, Innovate UK. --- ## Recommended financial model - **Archetype + why**: B2B life sciences reagent / ingredient sales model (volume × price P&L). Multus sells a physical product (growth media) to other companies at volume. The right model is a **bottoms-up volume/price revenue model** with COGS (formulation, manufacturing, packaging), gross margin build, and a 3-statement output. Not a SaaS, marketplace, or consumer model. Closest analogy: specialty chemical / reagent company (e.g., early-stage Sigma-Aldrich-type supplier to an emerging industry). - **Forecast horizon & granularity**: 5 years (2024–2028), monthly for Year 1, quarterly for Years 2–3, annual for Years 4–5. Industry commercialisation is mid-decade; model needs to capture the R&D → scale-up → commercial inflection. - **Key drivers & assumptions**: - **Number of cultivated meat customer accounts** - starts small (5–15 R&D labs), grows as industry scales. - **Volume per customer per period (litres of growth media)** - R&D phase: low volumes (10s of litres); scale-up phase: 100s–1,000s of litres. - **ASP per litre of growth media** - conventional FBS ~$300–$1,000/litre; Multus likely priced at a discount to FBS or premium for animal-free certification. - **Growth of cultivated meat industry / addressable customer base** - $630bn market by 2040; CAGR redacted;. - **Gross margin** - specialty reagent/media companies typically 60–75% GM at scale; early stage likely lower due to small batch manufacturing. - **Growth media share of cultivated meat production cost** - stated as ">X%" (redacted); industry literature suggests ~50–80%. - **R&D / headcount** - early team of 3 co-founders plus lab staff. - **Product mix** - three SKUs (Proliferum M, Serum P, im A);. - **10:1 concentrate ratio** for Proliferum M - reduces shipping volume/cost, improves economics vs. dilute competitors. - **Scenarios (Base / Bull / Bear)**: - **Base**: industry adoption of cultivated meat proceeds at moderate pace; Multus wins 10–15% of accessible early market; reaches £5–10M revenue by Year 5. - **Bull**: cultivated meat regulatory approval accelerates in UK/EU/Singapore; multiple large food companies contract Multus as exclusive supplier; pricing power maintained. - **Bear**: cultivated meat industry stalls (regulatory/consumer), compressing demand; large pharma suppliers (e.g., Merck/Sigma) enter with competing animal-free products; Multus squeezed on price. - **Flex variables**: customer acquisition pace, ASP, gross margin trajectory, industry CAGR. - **Required sheets / outputs**: 1. Assumptions - all drivers, scenarios toggleable. 2. Revenue build - customers × volume × price, by product SKU. 3. COGS & gross margin - manufacturing cost per litre, scaling curve. 4. OpEx - R&D, headcount, G&A. 5. Income Statement (P&L). 6. Cash flow - burn rate and runway (critical for fundraising context). 7. Balance sheet (simple: cash, inventory, AR/AP). 8. Funding / runway - how long does the raise last at different burn rates. 9. Sensitivity table - GM% and ASP vs. revenue/EBITDA. ## Frequently asked questions ### Is the Multus Media financial model free? Yes. The Multus Media model is a free Excel download with live formulas. ### Can I change the assumptions? Yes. The workbook is editable and its live formulas recalculate when assumptions change.